SCHEMBL4267972

SCHEMBL4267972

O=C1C2=C(C(=O)N1O)[C@H]1CCC2C1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1072615 1.00 ALDH1A1 (0.32) ALDH1A1TDP1ELANE
SCHEMBL9593176 0.75 KMT2A (0.33) ALDH1A1
SCHEMBL9628044 0.70 ALDH1A1 (0.41) ALDH1A1
SCHEMBL9705145 0.70 ALDH1A1 (0.38) ALDH1A1
SCHEMBL7347918 0.69 SLC6A3 (0.33) ELANE
SCHEMBL9493729 0.69 ALDH1A1 (0.44) ALDH1A1
SCHEMBL9626558 0.69 ALDH1A1 (0.44) ALDH1A1
SCHEMBL9626581 0.69 ALDH1A1 (0.44) ALDH1A1
SCHEMBL2077444 0.66 CASP3 (0.40) ALDH1A1TDP1
SCHEMBL12583840 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014081299-A1 ACTIVATABLE LIPOSOMES TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 WO disclosed
US-7608687-B2 Releasable linkage and compositions containing same ALZA CORPORATION (US) 2009-10-27 US disclosed
US-7592307-B2 Releasable linkage and compositions containing same ALZA CORPORATION (US) 2009-09-22 US disclosed
US-20080279922-A1 Releasable linkage and compositions containing same ALZA CORPORATION 2008-11-13 US disclosed
US-20080152702-A1 Releasable linkage and compositions containing same ZALIPSKY SAMUEL 2008-06-26 US disclosed
US-7390780-B2 Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification ALZA CORPORATION (US) 2008-06-24 US disclosed
EP-1880736-A1 Releasable linkage and composition containing same Alza Corporation (US) 2008-01-23 EP disclosed
US-7285622-B2 Releasable linkage and compositions containing same ALZA CORPORATION (US) 2007-10-23 US disclosed
US-7238368-B2 Releasable linkage and compositions containing same ALZA CORPORATION (US) 2007-07-03 US disclosed
US-7112337-B2 Liposome composition for delivery of nucleic acid ALZA CORPORATION (US) 2006-09-26 US disclosed
US-20020172711-A1 Therapeutic liposome composition and method of preparation ALZA CORPORATION 2002-11-21 US disclosed
US-20020128195-A1 Releasable linkage and compositions containing same ALZA CORPORATION 2002-09-12 US disclosed
EP-1214935-A2 Fusogenic liposome composition and method SEQUUS PHARMACEUTICALS, INC. (US) 2002-06-19 EP disclosed
US-6342244-B1 HYDROPHILIC POLYMER COVALENTLY YET REVERSIBLY LINKED TO A AMINE-CONTAINING LIGAND THROUGH A DITHIOBENZYL LINKAGE; MODIFICATION OF VARIOUS SUBSTRATES, SUCH AS POLYPEPTIDES, DRUGS AND LIPOSOMES; UPON CLEAVAGE OF THE LINKAGE, THE LIGAND ALZA CORPORATION 2002-01-29 US disclosed
EP-1173221-A2 RELEASABLE LINKAGE AND COMPOSITIONS CONTAINING SAME Alza Corporation (US) 2002-01-23 EP disclosed
US-6224903-B1 HYDROPHILIC-HYDROPHOBIC POLYMERS SEQUUS PHARMACEUTICALS, INC. 2001-05-01 US disclosed
WO-2000064483-A2 RELEASABLE LINKAGE AND COMPOSITIONS CONTAINING SAME ALZA CORPORATION (US) 2000-11-02 WO disclosed
EP-0932391-A2 FUSOGENIC LIPOSOME COMPOSITION AND METHOD SEQUUS PHARMACEUTICALS, INC. (US) 1999-08-04 EP disclosed
US-5891468-A DRUG DELIVERY SEQUUS PHARMACEUTICALS, INC. (US) 1999-04-06 US disclosed
WO-1998016202-A2 FUSOGENIC LIPOSOME COMPOSITION AND METHOD SEQUUS PHARMACEUTICALS, INC. (US) 1998-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128195-A1 Releasable linkage and compositions containing same CD44, ILK, CD69 ALDH1A1 1574/4885TDP1 378/4885ELANE 209/4885
US-20080279922-A1 Releasable linkage and compositions containing same CD44, SHMT1, HCAR1 ALDH1A1 718/4885TDP1 603/4885ELANE 620/4885
US-20080152702-A1 Releasable linkage and compositions containing same CD44, ILK, CD69 ALDH1A1 1574/4885TDP1 378/4885ELANE 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.